Advanced Biomed Inc. has entered into an agreement to sell 100% of the issued and outstanding shares of its Hong Kong subsidiary, Advanced Biomed (HK) Limited, to an unrelated third party, Wei Ha Hui, for a total purchase price of US$23,000. As part of the transaction, all intellectual property held by the Hong Kong subsidiary, including that of Shanghai Sglcell Biotech Co., Ltd., has been transferred to the buyer. The decision was made to address evolving regulatory requirements in China and to streamline the company’s clinical trials and product development through its Taiwan subsidiary. The transaction closed on December 23, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advanced Biomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9618227-en) on December 30, 2025, and is solely responsible for the information contained therein.